October 14th 2024
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
September 17th 2024
September 5th 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Eyes and the Periorbital Area Are Vulnerable to Damage From the Sun, Need Special Protection
June 1st 1995NEW YORK--If the face is the area of the body most vulnerable to sun damage, the eyes are in need of special protection, Rene S. Rodriguez-Sains, MD, said at a media conference sponsored by the Skin Cancer Foundation. Malignancies of the eyes and periocular area are particularly serious because of their proximity to the brain and other vital structures, he said.
Cancer Vaccine Made From Purified Tumor Antigen Enters Phase III Melanoma Trials
May 1st 1995NEW YORK--A mollusk protein turned out to be the best carrier for a cancer vaccine being developed by Philip O. Livingston, MD, at Memorial Sloan-Kettering Cancer Center. This approach to augmenting the immunogenicity of the GM2 ganglioside tumor antigen is about to be tested in phase III randomized trials of melanoma patients who are free of detectable disease after surgery but are at high risk for recurrence.
WHO Melanoma Study: Interferon Boosts Disease-Free Survival
March 1st 1995LISBON, Portugal--Adjuvant immunotherapy with low-dose interferon (IFN)-alfa-2a (Roferon-A) boosts disease-free survival by a significant 40% in melanoma patients with regional lymph node metastasis, according to the findings of the latest multicenter World Health Organization (WHO) Melanoma Programme trial.